JP2022545542A5 - - Google Patents

Info

Publication number
JP2022545542A5
JP2022545542A5 JP2022513277A JP2022513277A JP2022545542A5 JP 2022545542 A5 JP2022545542 A5 JP 2022545542A5 JP 2022513277 A JP2022513277 A JP 2022513277A JP 2022513277 A JP2022513277 A JP 2022513277A JP 2022545542 A5 JP2022545542 A5 JP 2022545542A5
Authority
JP
Japan
Prior art keywords
pyrazole
ethoxycyclohexyl
difluoropyridine
thiazole
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545542A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048528 external-priority patent/WO2021041898A1/en
Publication of JP2022545542A publication Critical patent/JP2022545542A/ja
Publication of JP2022545542A5 publication Critical patent/JP2022545542A5/ja
Priority to JP2025203023A priority Critical patent/JP2026053335A/ja
Pending legal-status Critical Current

Links

JP2022513277A 2019-08-30 2020-08-28 ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法 Pending JP2022545542A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025203023A JP2026053335A (ja) 2019-08-30 2025-11-25 ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962894547P 2019-08-30 2019-08-30
US62/894,547 2019-08-30
PCT/US2020/048528 WO2021041898A1 (en) 2019-08-30 2020-08-28 Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025203023A Division JP2026053335A (ja) 2019-08-30 2025-11-25 ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法

Publications (2)

Publication Number Publication Date
JP2022545542A JP2022545542A (ja) 2022-10-27
JP2022545542A5 true JP2022545542A5 (cg-RX-API-DMAC10.html) 2023-09-04

Family

ID=72473975

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513277A Pending JP2022545542A (ja) 2019-08-30 2020-08-28 ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法
JP2025203023A Pending JP2026053335A (ja) 2019-08-30 2025-11-25 ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025203023A Pending JP2026053335A (ja) 2019-08-30 2025-11-25 ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法

Country Status (21)

Country Link
US (3) US11370787B2 (cg-RX-API-DMAC10.html)
EP (1) EP4003990A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022545542A (cg-RX-API-DMAC10.html)
CN (2) CN121159524A (cg-RX-API-DMAC10.html)
AR (1) AR119857A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020335903B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022003564A2 (cg-RX-API-DMAC10.html)
CA (1) CA3152264A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022002993A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220085A (cg-RX-API-DMAC10.html)
DO (1) DOP2022000047A (cg-RX-API-DMAC10.html)
EC (1) ECSP22014379A (cg-RX-API-DMAC10.html)
IL (1) IL290882B2 (cg-RX-API-DMAC10.html)
JO (1) JOP20220050A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022002292A (cg-RX-API-DMAC10.html)
PE (1) PE20220970A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022550466A1 (cg-RX-API-DMAC10.html)
PY (1) PY2049213A (cg-RX-API-DMAC10.html)
SA (1) SA522431791B1 (cg-RX-API-DMAC10.html)
TW (1) TWI870449B (cg-RX-API-DMAC10.html)
WO (1) WO2021041898A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545542A (ja) 2019-08-30 2022-10-27 ライジェル ファーマシューティカルズ， インコーポレイテッド ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法
WO2022187303A1 (en) * 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
EP4399208A4 (en) * 2021-09-08 2025-07-16 Rigel Pharmaceuticals Inc IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE CONDITIONS ASSOCIATED WITH RESPIRATORY VIRUS INFECTION
ES3075943T3 (en) * 2022-03-23 2026-08-10 Rigel Pharmaceuticals Inc Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2026122888A1 (en) * 2024-12-06 2026-06-11 Rigel Pharmaceuticals, Inc. Pharmaceutical compositions comprising 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1h-pyrazol -4-yl)carbamoyl)thiazol-2-yl)-1h-pyrazol-1-yl)ethyl phosphate or its salts
US20260159538A1 (en) * 2024-12-06 2026-06-11 Rigel Pharmaceuticals, Inc. Solid forms of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1h-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1h-pyrazol-1-yl)ethyl phosphate and salts thereof, and their pharmaceutical compositions and uses
US20260158048A1 (en) 2024-12-06 2026-06-11 Rigel Pharmaceuticals, Inc. Methods of treatment
CN119950825B (zh) * 2025-03-13 2025-07-22 北京工业大学 基于压电驱动的自适应释药电纺覆膜气管支架的制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
CA2031376A1 (en) 1989-12-04 1991-06-05 Bahram Farhadieh Single layer transdermal drug administration system
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
CA2123809A1 (en) 1991-12-18 1993-06-24 Debra L. Wilfong Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2006070202A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives having kinase modulating activity
SI2206707T1 (sl) 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolkarboksamidna spojina ali njena sol
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
US8987309B2 (en) 2009-04-17 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles
EP2243481A1 (en) 2009-04-24 2010-10-27 PamGene B.V. Irak kinase family as novel drug target for Alzheimer
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
CA2794801C (en) 2010-04-07 2019-01-15 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
RU2632900C2 (ru) 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применение
WO2012072685A1 (en) 2010-12-02 2012-06-07 Katholieke Universiteit Leuven, K.U.Leuven R&D Irak-related interventions and diagnosis
HUE029617T2 (en) 2010-12-20 2017-03-28 Merck Serono Sa Indazolyl triazole derivatives as IRAK inhibitors
EP3239154A1 (en) 2011-01-10 2017-11-01 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN103347873A (zh) 2011-02-09 2013-10-09 日产化学工业株式会社 吡唑衍生物和有害生物防除剂
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2760857A1 (en) 2011-09-27 2014-08-06 F.Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
TW201728592A (zh) 2012-01-10 2017-08-16 林伯士艾瑞斯公司 Ｉｒａｋ抑制劑及其用途
WO2014048939A1 (en) 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
JP6483624B2 (ja) 2013-02-07 2019-03-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリダジノン−アミド誘導体
ES2639717T3 (es) 2013-02-07 2017-10-30 Merck Patent Gmbh Derivados de piridazinona macrocíclicos
ES2728403T3 (es) 2014-01-09 2019-10-24 Merck Patent Gmbh Derivados de pirimidin pirazolilo y su uso como inhibidores de IRAK
LT3221306T (lt) 2014-11-20 2020-03-10 Merck Patent Gmbh Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas
DK3286181T3 (da) * 2015-04-22 2021-04-06 Rigel Pharmaceuticals Inc Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne
CN110099899B (zh) * 2016-10-26 2024-01-02 里格尔药品股份有限公司 用作irak抑制剂的噁唑衍生物及其制备方法
JP2022545542A (ja) * 2019-08-30 2022-10-27 ライジェル ファーマシューティカルズ， インコーポレイテッド ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法

Similar Documents

Publication Publication Date Title
US11897866B2 (en) Heteroaryl inhibitors of PAD4
KR102434308B1 (ko) 아르기닌 활성 억제용 조성물 및 방법
JP7713934B2 (ja) Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形
TWI870449B (zh) 吡唑化合物，其配製物以及使用該化合物和/或配製物之方法
WO2020156285A1 (zh) 一种苯并吡啶酮杂环化合物及其用途
ES2953834T3 (es) Derivados novedosos de ftalazinona y su procedimiento de fabricación
JP2023531390A (ja) フタラジノン化合物、並びにその調製方法及びその医薬用途
RU2010137635A (ru) Гетероциклические антивирусные соединения
JP2019517548A (ja) メニン−ｍｌｌ相互作用の阻害剤
IL321433A (en) Purines 2,6,9 trimethylated
JP2025138724A (ja) Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート
JP2022551316A (ja) Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
US20220288047A1 (en) Method for treating a disease or condition using a pyrazole compound or formulation thereof
IL295456A (en) Heterocyclic compounds for modulating nr2f6
CN112979532A (zh) 邻苯二甲酰亚胺类化合物、制备方法和应用
CN111491937A (zh) 作为精氨酸酶抑制剂的杂环化合物
JP2024512046A5 (cg-RX-API-DMAC10.html)
WO2025222127A2 (en) Topoisomerase inhibitors, antibody drug conjugate linkers, methods of making, and methods of use thereof
NZ728685A (en) New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
HK40104808A (en) Fused ring compound as protein degradation agent as well as preparation method and use thereof
NZ728685B2 (en) New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
TW202114650A (zh) 6,8-雙(苄基磺醯基)辛酸之氘化衍生物
EA046545B1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство